StockWatch
·
Q2 FY-2027 RESULTS · GRANULES

Granules India Q2 FY27: PAT Surges 39% YoY to ₹182 Cr, Margin Just Shy of Guided Band

PAT +39.23% YoY · revenue +20.28% · margins expanding · beat vs street

Q2 FY27 resultsGRANULESGRANULES INDIA LTD.-$02 Nov 2026 · 3 min read
Revenue

₹1,559.97 Cr

+20.28% YoY

PAT (consolidated)

₹181.84 Cr

+39.23% YoY

Net margin

11.58%

+1.5pp YoY

EPS

₹7.22

Granules India's consolidated revenue crossed ₹1,500 Cr for the first time in Q2 FY27, at ₹1,559.97 Cr — up 20.3% YoY and 5.6% QoQ, matching the 20% YoY growth management cited in its own press release. Consolidated PAT of ₹181.84 Cr grew 39.2% YoY, well ahead of revenue growth, though it was almost flat QoQ (+1.0%) after a strong Q1. Standalone PAT was ₹108.52 Cr on revenue of ₹947.82 Cr (EPS ₹4.31); consolidated basic EPS came in at ₹7.22, down marginally from ₹7.26 in Q1 despite higher profit, because the company allotted 2.49 Cr new equity shares this quarter on warrant conversion, diluting the base.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹1,559.97 Cr+5.6%+20.3%
Expenses₹1,327.24 Cr+7.2%+18.5%
PAT₹181.84 Cr+1.04%+39.23%
Net margin11.58%-0.6pp+1.5pp
EPS₹7.22-0.6%+34.2%

EBITDA was ₹337.6 Cr, a 21.64% margin — up from 21.45% a year ago (margin expansion YoY) but down from 22.95% in Q1, and below the 22-23% band management had guided to sustain through FY27. Net profit margin shows the same pattern: 11.66% versus 10.08% YoY, but down from 12.17% QoQ. Management's own framing attributes the squeeze to "higher input and logistics costs from tensions in West Asia," and flags that "cost pressures will persist" while the company works with customers to pass them through "with a lag" — so the FY27 margin guidance is running behind plan this quarter rather than abandoned. No exceptional items hit Q2 FY27 or the year-ago quarter, so both the revenue and profit growth above are on a clean, comparable base.

₹
781816.51852.03887.54923.05820.707-3008-2109-1510-0811-02Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹820.7, down 3.1% over the past month of trading.

₹ Cr
075.25150.5225.76112.64Q1 FY26rev ₹1,210 Cr130.61Q2 FY26rev ₹1,297 Cr111.58Q3 FY26rev ₹895 Cr201.57Q4 FY26rev ₹1,471 Cr179.96Q1 FY27rev ₹1,477 Cr181.84Q2 FY27rev ₹1,560 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

No exceptional items this quarter (unlike H1 FY26's ~₹25.9 Cr Senn Chemicals acquisition cost), so growth is on a clean like-for-like base

What management guided (1 FY-2027 call)
FY27 capex ₹600 Cr (₹89 Cr spent Q1); EBITDA margins 22-23% expected to continue; peptide CDMO target PAT positive on annual basis FY27; 9 approvals from GGP pending FDA clearance of Gagillapur facility; FY27 growth continues (specific number deferred).

— This quarter: missed

Our pre-result preview had set the on-plan bar at ₹1,420-1,500 Cr revenue, 22-23% EBITDA margin and double-digit PAT growth, built on consensus that was 87.5% Buy-rated (median target ₹765) and a Q1 that had already beaten Motilal Oswal's revenue/EBITDA/PAT estimates. Actual revenue (₹1,559.97 Cr) and PAT growth (39.2%) both beat that range; margin alone missed, landing below the bottom of the guided band. On the pipeline side, management says it filed two more potential first-to-file ANDAs in H1 FY27 (three total), continuing the stated shift to complex generics and peptide CDMO — a business the prior concall had targeted for annual PAT breakeven in FY27, though this filing discloses no segment-level CDMO numbers to verify that independently. The quarter also carried two other threads from the event record: the Gagillapur facility underwent a fresh USFDA inspection that concluded October 30, 2026 (closing out a February 2025 warning letter tied to an August-September 2024 inspection, per the auditor's notes), and the promoter group completed its warrant-to-equity conversion (2.49 Cr shares, ₹1,096.1 Mn), which management says leaves the group with ₹828 Cr of net cash; two new wholly-owned subsidiaries were also incorporated during the quarter (Brazil and, just after quarter-end, Mexico).

  • W1

    H2 FY27 EBITDA margin recovery toward the 22-23% guided band, given management's own warning that cost pressures will persist

  • W2

    Peptide CDMO segment progress toward the FY27 annual PAT-breakeven target flagged last concall — no segment numbers disclosed this quarter

  • W3

    Any further USFDA correspondence on Gagillapur following the October 30, 2026 inspection, relevant to the 9 pending GGP approvals flagged last quarter

Informational and educational content only. Not investment advice.